3,4-CTMP

Contraindicated in individuals with pre-existing cardiac valve disease or pulmonary arterial hypertension. 3,4-CTMP acts as a 5-HT₂B receptor agonist (Luethi 2018), a validated mechanism for valve fibrosis as seen with fenfluramine and ergot alkaloids. This contraindication is unique among phenidate stimulants.

Contraindicated in individuals with hypertension, coronary artery disease, arrhythmias, or structural heart defects. The compound's potent norepinephrine reuptake inhibition produces pronounced sympathomimetic cardiovascular stress exceeding that of other phenidate stimulants.

Contraindicated in individuals with epilepsy or other seizure disorders. Stimulants lower seizure threshold through excessive catecholaminergic stimulation, consistent with the class mechanism of all DAT/NET inhibitors.

Relative contraindication in individuals with generalized anxiety disorder, panic disorder, or other anxiety conditions. The compound's potent NET inhibition drives noradrenergic arousal that may exacerbate anxiety symptoms.

Relative contraindication in individuals with a history of stimulant use disorder. Davidson et al. (2018) concluded 3,4-CTMP likely carries the highest addictive liability among phenidate NPS studied, based on dopamine efflux magnitude. User reports consistently note compulsive redosing urge.

Relative contraindication in individuals with significant hepatic impairment. If metabolism depends on hepatic carboxylesterases (inferred from methylphenidate class), impaired clearance could substantially prolong the already-long duration of action.

No reproductive safety data exists for 3,4-CTMP. Standard stimulant contraindication applies due to potential fetal harm from sympathomimetic vasoconstriction and catecholaminergic effects on fetal development.

Concurrent use of monoamine oxidase inhibitors is absolutely contraindicated. Combined catecholamine reuptake inhibition and MAO inhibition risks hypertensive crisis through synergistic catecholamine potentiation.

Relative contraindication with concurrent SSRIs, SNRIs, or other SERT-active compounds. 3,4-CTMP's dual serotonergic action (SERT reuptake inhibition + 5-HT₂B agonism) creates theoretical serotonin toxicity risk not present with purely catecholaminergic stimulants.